The cost of growth hormone therapy in Italy can reach nearly €100,000 for a full course of pediatric treatment. To manage these costs, the Italian healthcare system has increasingly embraced Biosimilars (like Omnitrope).

Biosimilars provide the same clinical results as the original "brand-name" drugs but at a lower cost to the SSN. AIFA guidelines encourage the use of these cost-effective options to ensure that the healthcare budget can cover all patients in need. Furthermore, new 2026 guidelines for "Price and Reimbursement Dossiers" require pharmaceutical companies to provide extensive evidence of "therapeutic innovation" to justify higher prices for new GH products.